Bristol-Myers Squibb Company [NYSE: BMY] gained 0.02% on the last trading session, reaching $65.72 price per share at the time. The company report on May 28, 2021 that U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1.
Zeposia, the first and only oral sphingosine 1-phosphate (S1P) receptor modulator approved for ulcerative colitis1, represents a new way of treating this chronic immune-mediated disease2.
Zeposia demonstrated significant improvements across all primary and key secondary efficacy endpoints – including clinical remission, clinical response, endoscopic improvement and endoscopic-histologic mucosal improvement – versus placebo at Week 10 and Week 52 in True North Phase 3 study1.
Bristol-Myers Squibb Company represents 2.24 billion in outstanding shares, while the company has a total market value of $146.72 billion with the latest information. BMY stock price has been found in the range of $65.60 to $66.21.
If compared to the average trading volume of 11.20M shares, BMY reached a trading volume of 6353367 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Bristol-Myers Squibb Company [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $75.37 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Bristol-Myers Squibb Company shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on April 30, 2021. The new note on the price target was released on April 13, 2021, representing the official price target for Bristol-Myers Squibb Company stock. Previously, the target price had yet another raise to $76, while Societe Generale analysts kept a Buy rating on BMY stock.
The Average True Range (ATR) for Bristol-Myers Squibb Company is set at 1.01, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 3.43. The Price to Book ratio for the last quarter was 3.91, with the Price to Cash per share for the same quarter was set at 5.79. Price to Free Cash Flow for BMY in the course of the last twelve months was 16.17 with Quick ratio for the last quarter at 1.50.
Trading performance analysis for BMY stock
Bristol-Myers Squibb Company [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.98. With this latest performance, BMY shares gained by 4.50% in over the last four-week period, additionally plugging by 4.58% over the last 6 months – not to mention a rise of 10.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 53.68, with the RSI for the last a single of trading hit 50.25, and the three-weeks RSI is set at 54.87 for Bristol-Myers Squibb Company [BMY]. The present Moving Average for the last 50 days of trading for this stock 64.46, while it was recorded at 66.32 for the last single week of trading, and 62.24 for the last 200 days.
Bristol-Myers Squibb Company [BMY]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Bristol-Myers Squibb Company [BMY] shares currently have an operating margin of +10.56 and a Gross Margin at +51.04. Bristol-Myers Squibb Company’s Net Margin is presently recorded at -21.20.
Return on Total Capital for BMY is now 4.76, given the latest momentum, and Return on Invested Capital for the company is -9.87. Return on Equity for this stock declined to -20.16, with Return on Assets sitting at -7.26. When it comes to the capital structure of this company, Bristol-Myers Squibb Company [BMY] has a Total Debt to Total Equity ratio set at 136.62. Additionally, BMY Total Debt to Total Capital is recorded at 57.74, with Total Debt to Total Assets ending up at 43.61. Long-Term Debt to Equity for the company is recorded at 130.00, with the Long-Term Debt to Total Capital now at 54.94.
Reflecting on the efficiency of the workforce at the company, Bristol-Myers Squibb Company [BMY] managed to generate an average of -$298,017 per employee. Receivables Turnover for the company is 4.54 with a Total Asset Turnover recorded at a value of 0.34.Bristol-Myers Squibb Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.60.
Bristol-Myers Squibb Company [BMY]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Bristol-Myers Squibb Company posted 1.63/share EPS, while the average EPS was predicted by analysts to be reported at 1.48/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Company go to 7.80%.
An analysis of insider ownership at Bristol-Myers Squibb Company [BMY]
There are presently around $107,231 million, or 75.20% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 196,665,309, which is approximately -1.342% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 176,410,048 shares of the stock with an approximate value of $11.59 billion in BMY stocks shares; and STATE STREET CORP, currently with $5.98 billion in BMY stock with ownership of nearly -3.414% of the company’s market capitalization.
Positions in Bristol-Myers Squibb Company stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,163 institutional holders increased their position in Bristol-Myers Squibb Company [NYSE:BMY] by around 73,707,774 shares. Additionally, 1,060 investors decreased positions by around 106,064,528 shares, while 273 investors held positions by with 1,451,855,548 shares. The mentioned changes placed institutional holdings at 1,631,627,850 shares, according to the latest SEC report filing. BMY stock had 149 new institutional investments in for a total of 6,051,751 shares, while 121 institutional investors sold positions of 8,630,225 shares during the same period.